INTRODUCTION AND OBJECTIVES: African American (AA) men have a higher incidence of and mortality from prostate cancer (PCa) than European American (EA) men. The potential biological determinants of these racial disparities are still unknown. Cancer genome evaluations with available clinical outcome data have been limited to EA populations. Here we characterize PCa genomes from a large cohort of AA men and identify the associations between genomic alterations and clinical outcomes.
METHODS: Cancer genomes from 205 AA men treated with radical prostatectomy (RP) were profiled using next-generation sequencing for somatic mutations and percent genome alteration (PGA; defined as percentage of tumor genome with copy number variation). Logistic regression and Cox proportional hazard analyses assessed the association of genomic alterations with pathologic and oncologic outcomes in multivariate models (adjusted for age, PSA, and pathologic grade and/or stage, when applicable). PGA was dichotomized by quartiles in analytical models ( 75th percentile vs >75th percentile).
RESULTS: The median PGA was 3.7% (IQR 0.9-9.4) and increased with pathologic grade (p<0.001) and stage (p[0.02). Median follow-up was 5 years. AA men with the highest quartile of PGA had significantly worse biochemical recurrence (BCR)-free survival (10 year: 33.5% vs 50.2%; p[0.006) and metastasis-free survival (10 year: 47.9% vs 89.0%; p<0.001) than men with lower quartiles of PGA. PGA was associated with increased risks of higher grade (OR 2.0, 95% CI 1.1-3.7, p[0.03), higher stage (OR 2.0, 95% CI 1.1-3.8, p[0.03), BCR (univariate: HR 1.9, 95% CI 1.2-3.2, p[0.01), and metastasis (HR 9.6, 95% CI 2.9-31.3, p<0.001). The most common somatic mutations were SPOP (12.5%, 123/184), FOXA1 (9.2%, 17/184), and TP53 (4.4%, 8/ 184). Only TP53 was associated with increased risks of adverse outcomes, including higher stage (OR 5.3, p[0.01) , BCR (non-significant univariate: HR 2.4, 95% CI 1.0-5.9, p[0.06), and metastasis (HR 9.5, 95% CI 2. 2-40.6, p[0.002) .
CONCLUSIONS: In AA men, PCa genome profiles reveal unique genomic alterations. Notably, PGA in AA men predicts adverse pathologic and oncologic outcomes after RP and can potentially be considered a prognostic biomarker in this racial group. This research highlights the increasing importance of racial ancestry in cancer genomics studies and in the development of precision medicine strategies. METHODS: Four centers contributed archived cancer-negative prostate biopsy tissue blocks from 129 patients. The non-tumor associated (NTA) controls were from patients who underwent 2 or more negative biopsies within 24 months. Tumor associated (TA) benign biopsies were from patients who were diagnosed with PC and underwent prostatectomy to confirm a final Gleason score of !7. After central re-review of slides, biopsy tissue was analyzed for DNA methylation using pyrosequencing, encompassing CpG sites across 6 genes. Predictive accuracy for PC detection was measured using ROC. The correlation of methylation for each CpG site in two biopsy samples was calculated for the entire cohort. Methylation variation was further elucidated in a subset of patients with four biopsy samples.
RESULTS: Patients diagnosed with GS !7 PC (TA, N[77) and the control group (NTA, N[52) demonstrate robust methylation differences across all CpG sites (p<0.05) at CpG shores near CAV1, EVX1, FGF1, NCR2, PLA2G16 and SPAG4. The CpG sites with the highest AUC value from each gene locus was selected for a comparison of methylation variation. Five of the six genes demonstrate higher correlation values in NTA than TA biopsies (p<0.05). Analyzing samples with 4 biopsies revealed this increase in methylation variation in TA biopsies across prostate regions from 5 of the above loci ( Figure) .
CONCLUSIONS: The methylation status of CAV1, EVX1, FGF1, NCR2, PLA2G16 and SPAG4 differ between TA and NTA normal prostate tissues marking a field of epigenetic susceptibility associated with the development of PC. That methylation is variable between biopsies across a single gland provides clues to the biology of multifocal PC development and could potentially be used to improve biomarker detection. (PCa) is the most common non-skin cancer among American men, and growing evidence suggests that targeting the tumor microenvironment (TME) could be essential in combating the progression of metastasis and resistance development in cancer. In this context, the colonystimulating factor 1 (CSF1)/colony-stimulating factor 1 receptor (CSF1R) axis has gained the most attention, and various approaches
